Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KK4277 in Healthy Volunteers and Patients With SLE or CLE
NCT05411016Phase 1Completed
- Sponsor
- Kyowa Kirin
- Start
- Aug 2022
- Primary completion
- Dec 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial in systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE) comparing Placebo with KK4277 (2 arms). Primary endpoint: Number of participants with adverse events. Started Aug 2022; status: completed.
02
Drugs
KK-4277
03
Conditions
systemic lupus erythematosus (SLE)cutaneous lupus erythematosus (CLE)
Beyond the preview
Go deeper on NCT05411016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05411016.